Review the results of pharmacoeconomic trials of antiplatelet drugs in the treatment of patients with acute coronary syndrome
| Autor: | S. K. Zyryanov, E. V. Dumchenko |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Качественная клиническая практика, Vol 0, Iss 3, Pp 36-42 (2018) |
| Druh dokumentu: | article |
| ISSN: | 2588-0519 2618-8473 |
| Popis: | The purpose of this literature review is to systematize and synthesis of the available data for the period 20132016 years of pharmacoeconomics evaluation on the application of modern antiplatelet agents in patients with acute coronary syndrome (ACS). Methods. We conduced search in PubMed system and RNITS keywords «pharmacoeconomis and ticagrelor», «cost-effectiveness and ticagrelor», «budget impact analysis and ticagrelor», «analysis and ticagrelor», «pharmacoeconomics and ticagrelor». The review considered approaches to modelling, identifying the main cost and performance criteria. Results. Based on our analysis of published from 2013 to 2016 years literature, it can be concluded that use of ticagrelor instead of clopidogrel in patients with ACS is the dominant technology in the world and Russian practice. The subject of the comparison is most often (81%) spoke of generic clopidogrel and the entire cohort of patients with ACS, without division into tactics of treatment (81%). In the structure of the published studies pharmacoeconomic prevails (95%) temporary retrospective focus of research with a long time horizon (more than 1 year - 88% of foreign studies). In conducting research using Markov modelling in 71% of cases and the analysis of «cost-effectiveness», 52% of researchers, all of them foreign, further analysed the «cost-utility». The cost analysis of 62% of the authors consider only direct medical costs account for 19% of direct medical costs and indirect costs. The main feature is the inclusion of Russian studies in the analysis of indirect costs is that foreign researchers are doing much less (only 17% of researchers). Conclusion. The analysis of pharmacoeconomic studies of ticagrelor can be recommended as a cost-effective method for the treatment of ACS patients, regardless of treatment strategy. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|